

Supplementary Table 2. Number needed to treat (NNT) for PASI response at weeks 12–16 and week 24 among bDMARD-naïve patients with active PsA (placebo as reference)

Treatment ^a	PASI50		PASI75		PASI90		PASI100	
	Posterior median values (95% credible interval)							
	Week 12-16	Week 24	Week 12-16	Week 24	Week 12-16	Week 24	Week 12-16	Week 24
Abatacept 10 mg/kg Q4W IV	4.12 (-41.64, 50.11)	4.59 (-61.8, 67.47)	6.70 (-86.27, 99.91)	7.24 (-118.33, 126.26)	13.19 (-212.68, 237.46)	12.93 (-250.44, 261.96)	28.25 (-571.98, 604.89)	24.73 (-559.54, 572.87)
Abatacept 125 mg SC	NA	12.83 (-119.13, 146.95)	NA	22.85 (-227.89, 277.89)	NA	45.36 (-486.02, 582.43)	NA	95.11 (-1074.96, 1315.53)
Adalimumab 40 mg Q2W	2.31 (1.89, 3.01)	1.66 (1.45, 2.01)	3.19 (2.41, 4.49)	1.91 (1.55, 2.51)	5.37 (3.72, 8.23)	2.55 (1.92, 3.65)	9.92 (6.12, 17.36)	3.69 (2.53, 5.91)
Apremilast 30 mg BID	4.04 (2.93, 6.27)	3.35 (2.14, 7.25)	6.53 (4.39, 10.90)	4.95 (2.77, 12.16)	12.80 (7.92, 23.15)	8.35 (4.13, 23.15)	27.25 (14.94, 56.07)	15.14 (6.54, 47.73)
Certolizumab pegol pooled doses ^b	3.36 (2.26, 6.28)	2.10 (1.71, 2.82)	5.21 (3.11, 10.94)	2.70 (2.01, 3.96)	9.80 (5.18, 23.14)	4.00 (2.72, 6.43)	20.12 (9.20, 55.16)	6.41 (3.92, 11.65)
Etanercept 25 mg BIW/50 mg QIW	3.91 (-26.87, 37.87)	3.32 (2.08, 7.64)	6.27 (-57.39, 75.18)	4.89 (2.67, 12.88)	12.22 (-142.93, 177.62)	8.23 (3.93, 24.55)	25.90 (-375.66, 450.83)	14.89 (6.18, 50.56)
Golimumab 50 mg Q4W	1.72 (1.42, 2.32)	1.44 (1.30, 1.72)	2.10 (1.54, 3.20)	1.52 (1.27, 2.01)	3.09 (1.99, 5.38)	1.86 (1.41, 2.73)	5.03 (2.80, 10.31)	2.47 (1.69, 4.11)
Infliximab 5 mg/kg Q8W	1.33 (1.24, 1.48)	1.40 (1.28, 1.64)	1.35 (1.20, 1.61)	1.45 (1.24, 1.86)	1.62 (1.32, 2.13)	1.73 (1.36, 2.46)	2.14 (1.59, 3.19)	2.24 (1.59, 3.61)
Ixekizumab 80 mg Q2W	1.41 (1.29, 1.64)	1.35 (1.25, 1.51)	1.50 (1.27, 1.93)	1.34 (1.19, 1.64)	1.90 (1.46, 2.75)	1.54 (1.27, 2.07)	2.68 (1.85, 4.40)	1.92 (1.45, 2.85)
Ixekizumab 80 mg Q4W	1.44 (1.3, 1.68)	1.43 (1.30, 1.68)	1.55 (1.31, 2.00)	1.51 (1.28, 1.95)	2.01 (1.54, 2.89)	1.84 (1.43, 2.61)	2.88 (1.98, 4.70)	2.43 (1.72, 3.85)
Secukinumab 150 mg Q4W	2.00 (1.77, 2.33)	2.34 (1.77, 3.62)	2.60 (2.17, 3.24)	3.12 (2.14, 5.38)	4.12 (3.22, 5.51)	4.81 (2.97, 9.17)	7.20 (5.03, 11.01)	7.98 (4.38, 17.12)
Secukinumab 300 mg Q4W	1.67 (1.52, 1.88)	2.25 (1.72, 3.45)	2.00 (1.72, 2.39)	2.96 (2.03, 5.08)	2.89 (2.33, 3.71)	4.49 (2.78, 8.58)	4.62 (3.37, 6.72)	7.37 (4.05, 15.86)
Tofacitinib 5 mg BID	2.49 (1.84, 3.98)	NA	3.52 (2.32, 6.39)	NA	6.09 (3.53, 12.55)	NA	11.54 (5.79, 27.63)	NA
Ustekinumab 45 mg Q12W	2.50 (2.00, 3.38)	1.93 (1.62, 2.45)	3.55 (2.61, 5.23)	2.40 (1.85, 3.31)	6.14 (4.11, 9.87)	3.44 (2.44, 5.20)	11.66 (6.89, 21.58)	5.34 (3.43, 9.08)
Ustekinumab 90 mg Q12W	NA	1.78 (1.53, 2.19)	NA	2.13 (1.70, 2.84)	NA	2.95 (2.17, 4.30)	NA	4.43 (2.95, 7.26)

^aMixed biologic-naïve and -experienced population for the following treatments: abatacept 10 mg/kg Q4W IV, secukinumab 150 mg Q4W, secukinumab 300 mg Q4W and placebo; ^bCertolizumab pegol pooled doses are 200 mg Q2W and 400 mg Q4W

bDMARD = biologic disease-modifying antirheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; NA = not available/no data for inclusion in the respective network; PASI50, 75, 90, 100 = 50%, 75%, 90% and 100% reduction from baseline in Psoriasis Area and Severity Index (PASI) score; PsA = psoriatic arthritis; QIW = once weekly; QxW = every x weeks; SC = subcutaneously